Health TrialsbyHealthPanel

A Study of Pyridostigmine in Postural Tachycardia Syndrome

ConditionPostural Tachycardia Syndrome
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age15-55
SponsorMayo Clinic

About this trial

This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt.

Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking.

Disqualifiers

Pregnant or lactating women

Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study

Hypothyroidism or hyperthyroidism

Clinically significant coronary artery disease

Trial design

Design model

Parallel

Treatments tested in this trial

  • pyridostigmine

    Drug

    one 180 mg capsule per day for 3 days

  • Placebo

    Drug

    one capsule per day for 3 days

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: pyridostigmineActive comparator 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in orthostatic symptoms using Composite Autonomic Symptom Scale (COMPASS) change

Time frame
3 days

Secondary outcomes

1

Heart rate response to head-up tilt

Time frame
3 days
2

Plasma norepinephrine change

Time frame
3 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Mayo Clinic

Lead sponsor

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Source ClinicalTrials.gov
Apply now